Zdrowie i gospodarka · 29/05/2026
FDA Releases Final Guidance on Bioequivalence Studies for ANDA Submissions
The FDA has released a final guidance for industry on conducting bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an Abbreviated New Drug Application (ANDA), providing recommendations for applicants and finalizing a draft guidance issued in 2021.